Abstracts Archive - Page 1842 of 2607 - ACR Meeting Abstracts

Abstract Number: 2823 • 2015 ACR/ARHP Annual Meeting
Gut Inflammation in HLA-B27 Transgenic Rats Alters the Monocyte Compartment and Its Osteoclastogenic Potential
C. Ansalone, L. Utriainen, S. W. F. Milling and C. S. Goodyear, Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Human HLA-B27 and β2-microglobulin transgenic rats (B27 rats), an animal model for spondyloarthropathies, spontaneously develop inflammatory colitis and bone loss. We have previously demonstrated…
Abstract Number: 2824 • 2015 ACR/ARHP Annual Meeting
Autoantibodies Against CD74 – a New Diagnostic Marker for Spondyloarthritis (SpA)
Bruno Larida, AESKU.DIAGNOSTICS INC, Oakland, CA
Background/Purpose: Spondyloarthritis (SpA) is a common debilitating inflammatory disorder. The pathogenesis of axial spondyloarthritis (axSpA) including ankylosing spondylitis (AS), although known to be strongly associated…
Abstract Number: 2825 • 2015 ACR/ARHP Annual Meeting
Characterization of Mesenchymal Stem Cells Generated from Axial Spondyloarthritis Patient-Derived Induced Pluripotent Stem Cells
Gerlinde Layh-Schmitt¹, Shajia Lu¹, Emily Lazowick¹, Stephen Brooks¹, Massimo Gadina¹ and Robert A. Colbert², ¹NIAMS/NIH, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Ankylosing spondylitis (AS) is an immune-mediated inflammatory disease associated with trabecular bone loss and concomitant aberrant bone formation in the spine. Over 40 genes…
Abstract Number: 2826 • 2015 ACR/ARHP Annual Meeting
Stimulation of Autophagy Reduces Misfolded HLA-B27 in a Rat Model of Spondyloarthritis
Fatemeh Navid¹, Gerlinde Layh-Schmitt¹ and Robert A. Colbert², ¹NIAMS/NIH, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: HLA-B27/human β2microglobulin transgenic rats develop spondyloarthritis (SpA) characterized by inflammation in the gut and peripheral joints by mechanisms that remain poorly defined, but do…
Abstract Number: 2827 • 2015 ACR/ARHP Annual Meeting
Analysis of HLA-B27 Transgenic Rats Reveals Specific Gut Transcriptome and Microbiome Signatures Associated with Inflammation
Tejpal Gill¹, Mark Asquith², Stephen Brooks¹, James T. Rosenbaum³ and Robert A. Colbert⁴, ¹NIAMS/NIH, Bethesda, MD, ²OHSU, Portland, OR, ³Devers Eye Institute, Legacy Hospital system, Portland, OR, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: HLA-B27 and human beta 2-microglobulin expression in rats (transgenic; TG) induces a spontaneous inflammatory disease resembling human spondyloarthritis (SpA) with associated gastrointestinal inflammation. While…
Abstract Number: 2828 • 2015 ACR/ARHP Annual Meeting
Profiling Immunogenic Bacteria within the Microbiota of ZAP-70 Mutant SKG Mice Associated with Spondyloarthritis and Ileitis Using IgA-SEQ
Linda Rehaume¹, Alicia Kang¹, Olga Zbarskaya¹, Jane Mullaney¹, Matthew Kim¹, Paraic O Cuiv¹, Nicola Angel², Philip Hugenholtz², Mark Morrison¹ and Ranjeny Thomas¹, ¹Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ²Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia
Background/Purpose: IgA production is the main barrier mechanism of mucosal surfaces. High affinity IgA is generated through T cell-dependent mechanisms and preferentially binds to invasive…
Abstract Number: 2829 • 2015 ACR/ARHP Annual Meeting
Enhanced Expression of the Transcription Factor T-Bet Alters Pro-Inflammatory Cytokine Profile in Ankylosing Spondylitis
Max C. Lau¹, Patricia Keith¹, Mary-Ellen Costello¹, Linda A. Bradbury¹, Kelly A. Hollis¹, Gethin P. Thomas², Matthew A. Brown^1,3 and Tony J. Kenna¹, ¹The University of Queensland Diamantina Institute, Brisbane, Australia, ²Translational Reserch Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ³Translational Research Institute, Brisbane, Australia
Background/Purpose: TBX21 encodes T-bet, a T-box transcription factor, and lies within a locus with genome-wide significant association with AS (rs11657479, odds ratio=1.13, P=6.16x10-10). T-bet is…
Abstract Number: 2830 • 2015 ACR/ARHP Annual Meeting
Synovial Fluid T Cells of Patients with Reactive Arthritis and Undifferentiated Spondyloarthropathy Respond to Salmonella Typhimurium Outer Membrane Protein a and Induces IL17 and IL23 Production By Synovial Fluid Mononuclear Cells
Ramnath Misra¹, Smriti Chaurasia¹, Ajit K Shashny² and Amita Aggarwal^3,4, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Central Institute of Medicinal and Aromatic Plants, Scientist, Lucknow, India, ³Clinical Immunology, Additional Professor Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India, ⁴Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: We have previously shown that synovial fluid mononuclear cells (SFMCs) of patients with Reactive arthritis (ReA) and undifferentiated Spondyloarthropathy (uSpA) proliferated to low molecular…
Abstract Number: 2831 • 2015 ACR/ARHP Annual Meeting
A Subset of Natural Killer Cells Are Expanded in Synovial Fluid of Patients with Reactive Arthritis and Undifferentiated Spondyloarthritis
Abhra Chandra Chowdhury, Smriti Chaurasia, Amita Aggarwal and Ramnath Misra, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: We have previously shown that there is an increase in IL-17 in the synovial fluid of patients with Reactive arthritis(ReA) and undifferentiated spondyloarthropathy(uSpA). Besides…
Abstract Number: 2832 • 2015 ACR/ARHP Annual Meeting
Characterization of Leukocyte Subsets in Ankylosing Spondylitis Patients
Yolanda Jiménez Gómez, Chary Lopez-Pedrera, Pilar Font, Patricia Ruiz-Limon, Carlos Perez-Sanchez, Nuria Barbarroja, M. Carmen Castro Villegas, Jerusalem Calvo-Gutierrez, MariCarmen Abalos-Aguilera, Alejandro Escudero-Contreras and Eduardo Collantes-Estevez, IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain
Background/Purpose: AS is a chronic inflammatory disease, of unknown aetiology, characterized by pathological ossification. We aimed: 1) To analyze the profile of inflammation, oxidative status…
Abstract Number: 2833 • 2015 ACR/ARHP Annual Meeting
Negative Regulator, MiR-23a, Down-Regulated in Psoriatic Arthritis. Implications for Disease Pathogenesis
Sarah Wade¹, Michelle Trenkmann¹, Trudy McGarry¹, Douglas J. Veale² and Ursula Fearon¹, ¹St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ²St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune-mediated inflammatory disease, characterised by proliferation of synovial tissue and progressive destruction of articular cartilage/bone associated with psoriasis.…
Abstract Number: 2834 • 2015 ACR/ARHP Annual Meeting
CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients
Anastasiya Muntyanu¹, Fatima Abji², Kun Liang³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. We previously identified C-X-C motif chemokine 10 (CXCL10) as…
Abstract Number: 2835 • 2015 ACR/ARHP Annual Meeting
Long-Term Improvements with Certolizumab Pegol in Joints and Extra-Articular Manifestations of Psoriatic Arthritis in Patients with and without Prior Anti-TNF Exposure
Dafna D. Gladman¹, Alice B. Gottlieb², Bengt Hoepken³, Luke Peterson⁴ and Oliver FitzGerald⁵, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Dermatology, Tufts Medical Center, Boston, MA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵Department of Rheumatology, St. Vincent’s University Hospital, UCD School of Medicine and Medical Sciences and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Previous reports of RAPID-PsA (NCT01087788) have demonstrated the efficacy of certolizumab pegol (CZP) in patients (pts) with psoriatic arthritis (PsA) over 96 weeks (wks),1…
Abstract Number: 2836 • 2015 ACR/ARHP Annual Meeting
Early Clinical Response Is a Better Predictor of Long-Term Remission Than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis
Filip van Den Bosch¹, Philip J. Mease², Joachim Sieper³, Dominique Baeten⁴, Nupun A. Varothai⁵, Aileen L. Pangan⁵ and In-Ho Song⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: ABILITY-2 has demonstrated the efficacy of adalimumab (ADA) vs. placebo (PBO) over 12 weeks (wk) in patients (pt) with peripheral spondyloarthritis (pSpA)1 and sustained…
Abstract Number: 2837 • 2015 ACR/ARHP Annual Meeting
Sulfasalazine Comedication: A Predictor of Reduced Long-Term Anti-TNF Switch in Ankylosing Spondylitis
Andrea Y. Shimabuco, Celio R. Gonçalves, Julio C. B. Moraes, Mariana G Waisberg, Percival D Sampaio-Barros, Cláudia Goldenstein-Schainberg, Eloisa Bonfá and Carla G.S. Saad, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-TNF agents are efficacious in the treatment of ankylosing spondylitis (AS). The switch to another TNF blockage can be an alternative in cases of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].